Home » ASTRAZENECA'S NEW ASTHMA TREATMENT GETS FDA APPROVAL
ASTRAZENECA'S NEW ASTHMA TREATMENT GETS FDA APPROVAL
The FDA has approved AstraZeneca's Symbicort for the treatment of asthma in patients ages 12 and older.
Symbicort, a twice-daily asthma therapy that combines budesonide, an inhaled corticosteroid, and formoterol, a rapid and long-acting beta2-agonist, will be available in U.S. markets in a pressurized metered dose inhaler by mid-2007, the company said.
The combination therapy of adding long-acting inhaled beta-agonists to inhaled corticosteroids is recommended by the NIH for long-term prevention and control of moderate and severe asthma.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May